COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. The Shifting Paradigm of Monoclonal Antibodies in COVID-19 Management: From Early Triumphs to Viral Resistance and Future Perspectives.Antibodies (Basel, Switzerland) · 2026
   Review
2. Rising incidence of stroke in survivors of severe COVID-19.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
   Article
3. The influence of Omicron on vaccine efficacy and durability: a neurology perspective.Clinical and experimental vaccine research · 2024
   Review
4. Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected.Naunyn-Schmiedeberg's archives of pharmacology · 2023
   Review
5. SARS-CoV-2 caused a surge in antibiotic consumption causing a silent pandemic inside the pandemic. A retrospective analysis of Italian data in the first half of 2022.Annales pharmaceutiques francaises · 2023
   Article
6. The direct correlation between microbiota and SARS-CoV-2 infectious disease.Inflammopharmacology · 2023
   Review
7. What Do We Know About the Smallpox Virus? A Journey Between Clinic and Therapy.Pharmaceutical research · 2023
   Article
8. Pharmacological Agents with Antiviral Activity against Monkeypox Infection.International journal of molecular sciences · 2022
   Review
9. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.Clinical drug investigation · 2022
   Observational
10. Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.Inflammopharmacology · 2022
    Article
11. Could Decreased Reporting of Suspected Adverse Reactions Generate Future Safety Concerns?Hospital pharmacy · 2022
    Article
12. Advances in the Omicron variant development.Journal of internal medicine · 2022
    Review
13. Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.Journal of reproductive immunology · 2022
    Review
14. A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?Immunologic research · 2022
    Review
15. Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.Molecular biology reports · 2022
    Article
16. Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021
    Review
17. Plausible Positive Effects of Statins in COVID-19 Patient.Cardiovascular toxicology · 2021
    Review
18. COVID-19 vaccines and decreased transmission of SARS-CoV-2.Inflammopharmacology · 2021
    Review
19. Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.Current research in pharmacology and drug discovery · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as